Tandem Diabetes Care, Inc. Q4 2025 Earnings Call Summary

Moby Intelligence

Fri, February 20, 2026 astatine 7:30 AM CST 3 min read

• Surpassed $1 cardinal successful yearly income successful 2025, driven by grounds fourth-quarter pump shipments and double-digit maturation successful some U.S. and planetary markets.

• Management is fundamentally reshaping the concern exemplary by transitioning to a 'pay-as-you-go' (PayGo) reimbursement operation successful the pharmacy transmission to trim diligent out-of-pocket barriers.

• The displacement to pharmacy is expected to treble the beingness gross per diligent portion streamlining the medicine process for healthcare providers and improving information visibility for payers.

• International maturation was supported by grounds income contempt the operational complexity of transitioning to nonstop commercialized operations successful the U.K., Switzerland, and Austria.

• Operational ratio improved significantly, with Q4 gross margins reaching a grounds 58% owed to manufacturing efficiencies and a simplification successful non-cash stock-based compensation.

• The institution expanded its addressable marketplace successful 2025 by launching Control-IQ+ for benignant 2 diabetes and integrating with FreeStyle Libre 3 Plus for t:slim, with plans to motorboat Dexcom's 15-day sensor integration successful the 2nd 4th of 2026.

• 2026 guidance assumes 10% to 11% maturation successful U.S. pump shipments, though gross maturation volition beryllium moderated by a $70 cardinal to $80 cardinal pricing headwind from the PayGo transition.

• Management expects the pharmacy transmission to yet correspond implicit 70% of U.S. shipments wrong 2 to 3 years, flipping the existent 80% reliance connected the DME channel.

• The institution plans to record for FDA 510(k) clearance for Mobi Tubeless successful Q2 2026, targeting a motorboat successful the 2nd fractional of the twelvemonth arsenic the world's archetypal spot pump with extended deterioration technology.

• International nonstop operations volition grow to further European markets successful Q4 2026, with anticipated ASP premiums of astatine slightest 30% implicit existent distributor pricing.

• Financial targets for 2026 see expanding gross margins to 56%-57% and achieving affirmative adjusted EBITDA of 5%-6% for the afloat year.

• The modulation to nonstop planetary operations includes a $15 cardinal headwind successful 2026 related to distributor destocking and inventory buybacks.

• The PayGo exemplary creates a near-term gross 'offset' due to the fact that pump gross is recognized implicit clip via proviso income alternatively than arsenic a ample upfront payment.

• Q1 2026 results are expected to bespeak emblematic seasonality, including a astir 30% diminution successful shipments from Q4 owed to U.S. security deductible resets.

• Management identified the request for caller doc prescriptions arsenic a insignificant friction constituent successful transitioning the existing 325,000-customer basal to the pharmacy channel.